Ryeqo is a once-daily oral combination of relugolix 40 mg (a gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces ovarian estradiol production, a hormone known to stimulate the growth of uterine fibroids), estradiol 1.0 mg, and norethisterone acetate 0.5 mg) indicated in Europe for the treatment of

● Uterine fibroids with mild to moderate symptoms

● Symptoms of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis